OBIO Orchestra BioMed Holdings, Inc.
Orchestra BioMed Holdings, Inc. (OBIO) is expected to report earnings on November 9, 2026, before the market open. The consensus earnings estimate is a loss of $0.41 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +3.3% since its last earnings release on August 10, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About Orchestra BioMed Holdings, Inc.
Orchestra BioMed is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships with leading medical device companies.
Sector
Healthcare
Industry
Biotechnology